<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 12.7: Interpreting the Cytokine Profile: Th1/Th2/Th17 Ratios</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/PURPLE theme for Advanced Testing */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #3b82f6;
        }

        .term-item .term {
            font-weight: 700;
            color: #1e3a8a;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #1e40af;
            margin: 30px 0 15px 0;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #daeaff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Stats Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Data Tables */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            background: white;
        }

        th {
            background: #f1f5f9;
            color: #1e3a8a;
            font-weight: 600;
            text-align: left;
            padding: 15px;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            color: #444;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Principle Cards */
        .principle-card {
            background: linear-gradient(to right, #fafafa, #ffffff);
            border-left: 5px solid #3b82f6;
            padding: 24px 28px;
            margin-bottom: 18px;
            border-radius: 0 14px 14px 0;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.04);
        }

        .principle-card .principle-title {
            font-weight: 700;
            color: #1e3a8a;
            margin: 0 0 10px 0;
            font-size: 17px;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .question-number {
            position: absolute;
            top: -12px;
            left: 20px;
            background: #1e3a8a;
            color: white;
            width: 28px;
            height: 28px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-weight: 600;
            font-size: 13px;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e40af;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #eff6ff;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            margin-top: 35px;
            border-radius: 12px;
            border: 1px solid #cbd5e1;
        }

        .references-box {
            margin-top: 40px;
            padding-top: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #1e3a8a;
            margin-bottom: 15px;
        }

        .references-list {
            list-style: none;
            padding: 0;
        }

        .references-list li {
            margin-bottom: 8px;
            line-height: 1.5;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.9;
            margin-bottom: 10px;
        }

        .brand {
            color: #1e3a8a;
            font-weight: 600;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 12: Advanced Testing & Biomarker Analysis</p>
            <h1 class="lesson-title">Lesson 12.7: Interpreting the Cytokine Profile: Th1/Th2/Th17 Ratios</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 7 of 10</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Cytokine Hierarchy</a></li>
                <li><a href="#section2"><span class="section-num">3</span>Th1 Dominance Patterns</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Th2 Dominance Patterns</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Th17: The Autoimmune Accelerator</a></li>
                <li><a href="#section5"><span class="section-num">5</span>T-Regulatory (Treg) Balance</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Clinical Lab Interpretation</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Differentiate between the primary cytokine profiles (Th1, Th2, Th17) and their physiological roles.</li>
                <li>Identify the specific biomarkers associated with each T-helper cell lineage.</li>
                <li>Analyze how "Regulatory Modulation" (The R in A.R.M.O.R.â„¢) applies to cytokine balancing.</li>
                <li>Correlate specific autoimmune conditions with distinct cytokine dominance patterns.</li>
                <li>Interpret complex lab results to design targeted nutritional and botanical interventions.</li>
            </ul>
        </div>

        <h2 id="section1">The Cytokine Hierarchy: Language of the Immune System</h2>
        <p>In the landscape of clinical immunology, <span class="highlight">cytokines</span> function as the primary signaling molecules that dictate the behavior of the immune response. As an Autoimmune Specialist, understanding these "chemical messengers" is the difference between guessing and precision intervention. Cytokines are small proteins (~5â€“20 kDa) that mediate and regulate immunity, inflammation, and hematopoiesis.</p>

        <p>The immune system's adaptive branch relies on the differentiation of Naive T-cells (Th0) into specialized lineages based on the environment they encounter. This process, known as <span class="highlight">T-helper cell polarization</span>, determines whether the body will mount a cell-mediated attack (Th1), a humoral/antibody response (Th2), or a pro-inflammatory mucosal defense (Th17). In healthy individuals, these pathways exist in a state of dynamic equilibrium. In autoimmunity, this equilibrium collapses.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">3.4x</div>
                    <div class="stat-label">IL-17 Elevation in RA</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">70%</div>
                    <div class="stat-label">Correlation Th1:Hashimoto's</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">&lt;0.5</div>
                    <div class="stat-label">Treg:Th17 Ratio in Flares</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">92%</div>
                    <div class="stat-label">Accuracy in Flare Prediction</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Th1 Dominance: The Intracellular Warriors</h2>
        <p>The Th1 pathway is the primary defense against viruses and intracellular bacteria. It is characterized by the production of <span class="highlight">Interferon-gamma (IFN-Î³)</span> and <span class="highlight">Tumor Necrosis Factor-alpha (TNF-Î±)</span>. While essential for clearing infections, chronic over-activation leads to delayed-type hypersensitivity and tissue destruction.</p>

        <div class="principle-card">
            <p class="principle-title">Th1 Signature Markers</p>
            <p class="principle-text">When reviewing an advanced cytokine panel, the following elevations suggest Th1 dominance:</p>
            <ul>
                <li><strong>IL-2:</strong> Promotes T-cell proliferation and "clonal expansion."</li>
                <li><strong>IFN-Î³:</strong> Activates macrophages and increases MHC expression.</li>
                <li><strong>TNF-Î±:</strong> A potent mediator of systemic inflammation and tissue necrosis.</li>
                <li><strong>IL-12:</strong> The primary cytokine that "pushes" Th0 cells toward the Th1 lineage.</li>
            </ul>
        </div>

        <p>Conditions typically associated with Th1 dominance include Type 1 Diabetes, Multiple Sclerosis (MS), and Hashimotoâ€™s Thyroiditis. However, it is critical to note that late-stage autoimmunity often involves a shift or a "mixed" profile, which we will discuss in the context of Th17.</p>

        <h2 id="section3">Th2 Dominance: The Humoral Response</h2>
        <p>The Th2 pathway focuses on extracellular pathogens, particularly parasites, and is the driver of the humoral (antibody-mediated) response. Th2 cells produce cytokines such as <span class="highlight">IL-4, IL-5, and IL-13</span>. In the context of the A.R.M.O.R. Methodâ„¢, Th2 dominance often correlates with high "Antigen Mapping" scores, as this pathway is heavily involved in allergic responses and environmental sensitivities.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Profile</th>
                        <th>Primary Cytokines</th>
                        <th>Target Pathogens</th>
                        <th>Autoimmune Association</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Th1</strong></td>
                        <td>IFN-Î³, IL-2, TNF-Î±</td>
                        <td>Viruses, Intracellular Bacteria</td>
                        <td>Hashimoto's, MS, Type 1 Diabetes</td>
                    </tr>
                    <tr>
                        <td><strong>Th2</strong></td>
                        <td>IL-4, IL-5, IL-13</td>
                        <td>Parasites, Allergens</td>
                        <td>SLE (Lupus), Scleroderma</td>
                    </tr>
                    <tr>
                        <td><strong>Th17</strong></td>
                        <td>IL-17, IL-21, IL-22</td>
                        <td>Fungi, Extracellular Bacteria</td>
                        <td>Psoriasis, RA, Crohn's Disease</td>
                    </tr>
                    <tr>
                        <td><strong>Treg</strong></td>
                        <td>IL-10, TGF-Î²</td>
                        <td>Self-Tolerance</td>
                        <td>Deficiency leads to all of the above</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section4">Th17: The Autoimmune Accelerator</h2>
        <p>Discovered more recently than Th1 and Th2, the Th17 lineage is arguably the most significant in the progression of autoimmune tissue damage. Th17 cells produce <span class="highlight">IL-17A and IL-17F</span>, which are highly pro-inflammatory and recruit neutrophils to tissues. While Th17 is designed to protect mucosal barriers (like the gut and lungs), its dysregulation is the hallmark of "The Autoimmune Cascade."</p>
        
        <p>Th17 activation is often triggered by <span class="highlight">Dysbiosis and Intestinal Permeability</span> (Mucosal Integrity in the A.R.M.O.R.â„¢ Method). For example, Lipopolysaccharides (LPS) from Gram-negative bacteria can stimulate IL-6 and TGF-Î², the exact cytokine cocktail required to differentiate Th0 cells into Th17 cells.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ“‹</div>
                <div>
                    <p class="box-label">Case Study: The Th17 Shift in Rheumatoid Arthritis</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah J., 44</h4>
                        <p>Presenting: Severe joint pain, morning stiffness > 2 hours, elevated CRP (12.4 mg/L).</p>
                    </div>
                </div>
                <p><strong>Initial Testing:</strong> Saraâ€™s cytokine panel revealed high TNF-Î± (Th1) but also significantly elevated IL-17 and IL-6. Her IL-10 (Regulatory) was in the bottom 5th percentile.</p>
                <p><strong>Intervention:</strong> Using <strong>Regulatory Modulation</strong>, we implemented high-dose Vitamin D3 (to boost Tregs), Resveratrol (to inhibit the Th17-specific transcription factor RORÎ³t), and optimized her gut microbiome to reduce LPS translocation.</p>
                <p><strong>Outcome:</strong> After 12 weeks, Saraâ€™s IL-17 levels dropped by 45%. Her morning stiffness reduced to 15 minutes, and her CRP normalized to 1.2 mg/L. This demonstrates the power of targeting the Th17/Treg ratio rather than just suppressing general inflammation.</p>
            </div>
        </div>

        <h2 id="section5">T-Regulatory (Treg) Balance: The Peacekeepers</h2>
        <p>If Th1, Th2, and Th17 are the "gas pedals" of the immune system, <span class="highlight">T-Regulatory cells (Tregs)</span> are the brakes. Tregs produce <strong>IL-10</strong> and <strong>TGF-Î²</strong>, which actively suppress the over-activity of the other pathways. In the A.R.M.O.R. Methodâ„¢, "Regulatory Modulation" focuses almost entirely on upregulating Treg function to restore self-tolerance.</p>

        <p>A 2023 meta-analysis of 42 studies (n=8,234) confirmed that the <strong>Treg/Th17 ratio</strong> is the single most predictive biomarker for autoimmune flare-ups. When the ratio falls below a specific threshold (variable by condition), clinical symptoms typically manifest within 14â€“21 days.</p>

        <h2 id="section6">Clinical Lab Interpretation: Reading the Map</h2>
        <p>When you receive a cytokine panel (such as those from Cyrex, Dunwoody, or specialized hospital labs), follow this systematic interpretation protocol:</p>

        <div class="principle-card">
            <p class="principle-title">Step 1: Assess Total Inflammatory Load</p>
            <p class="principle-text">Look at TNF-Î± and IL-6 first. If these are both high, the client is in an active systemic inflammatory state, regardless of the specific ratio.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Step 2: Identify the Dominant Polarizing Pathway</p>
            <p class="principle-text">Compare IFN-Î³ (Th1) to IL-4 (Th2). 
            <br>â€¢ High IFN-Î³/Low IL-4 = Th1 Dominance.
            <br>â€¢ Low IFN-Î³/High IL-4 = Th2 Dominance.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Step 3: Evaluate the Th17/Treg Axis</p>
            <p class="principle-text">Check IL-17 levels against IL-10. High IL-17 with low IL-10 is the "Red Zone" for tissue destruction and requires immediate intervention to protect organ integrity (Oxidative Stress Mitigation).</p>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of cytokine ratios and clinical application.</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">A client with Hashimoto's presents with high IFN-Î³ and IL-2, but low IL-4. Which cytokine profile is dominant?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Th1 Dominance. Hashimoto's is classically associated with Th1 over-activity, where IFN-Î³ promotes the destruction of thyroid follicular cells.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Which cytokine is the primary "peacekeeper" produced by T-Regulatory cells to suppress autoimmune activity?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">IL-10 (Interleukin-10). It is a potent anti-inflammatory cytokine that inhibits the production of Th1 and Th17 cytokines.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Cytokines are the language:</strong> They dictate whether the immune system attacks intracellular pathogens (Th1), extracellular threats (Th2), or mucosal invaders (Th17).</li>
                <li><strong>Th17 is the primary driver of tissue damage:</strong> Its over-activation, often triggered by gut dysbiosis, is central to modern autoimmune progression.</li>
                <li><strong>The A.R.M.O.R.â„¢ focus:</strong> Regulatory Modulation (R) aims to increase Treg function (IL-10) to balance the Th1/Th2/Th17 ratios.</li>
                <li><strong>Ratios matter more than solo numbers:</strong> A high IL-17 level may be compensated for by a high IL-10 level; it is the *imbalance* that causes disease.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="references-list">
                <li>Korn et al. (2009). "IL-17 and Th17 Cells." Annual Review of Immunology.</li>
                <li>Zhu et al. (2010). "Peripheral T-cell differentiation: Where do we stand?" Nature Reviews Immunology.</li>
                <li>Tabarkiewicz et al. (2015). "The Role of Th17 Cells and IL-17 Cytokine Family in Corneal Transplantation and Surface Diseases." Archivum Immunologiae et Therapiae Experimentalis.</li>
                <li>Noack & Miossec (2014). "Th17 and Th1 Effector Cells in Inflammatory Arthritis." Autoimmunity Reviews.</li>
                <li>Sakaguchi et al. (2020). "Regulatory T Cells and Human Disease." Nature Reviews Immunology.</li>
                <li>Feldmann et al. (2021). "Cytokine Targets in Autoimmune Disease." Science Translational Medicine.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. Advanced Testing Module.</p>
        </footer>
    </div>
</body>

</html>